Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story

Annals of Oncology

Volumn 21, Issue 7, 2009, Pages 1486-1491

  Bari, A ^a   Marcheselli, L ^a   Sacchi, S ^a   Marcheselli, R ^a   Pozzi, S ^a   Ferri, P ^b   Balleari, E ^c   Musto, P ^d   Neri, S ^e   Spiriti, M A Aloe ^a   Cox, M C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e Papardo Hospital   (Italy)

Author keywords

Clinical trials; DLBCL; Innovative treatments; NHL; Prognostic models; Rituximab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; VALIDATION STUDY;

EID: 77954261226     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp531     Document Type: Article

References (23)

1. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
2. Pfreundschuh M, Trü mper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
3. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
4. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995-1007.
5. Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
6. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207-4213.
7. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.
8. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
9. Cox MC, Nofroni I, Ruco L et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008; 49: 1745-1751.
10. Silingardi V, Federico M, Cavanna L et al. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma 1995; 17: 313-320.
11. Federico M, Luminari S, Gobbi PG et al. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. Eur J Haematol 2006; 76: 217-229.
12. Gobbi PG, Ghirardelli ML, Avanzini P et al. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Haematologica 2000; 85: 263-268.
13. Gobbi PG, Broglia C, Valentino F et al. The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). Ann Oncol 2006; 17: 676-682.
14. Di Renzo N, Luminari S, Montanini A et al. Early response to a short course of induction chemotherapy overcomes the prognostic role of IPI in patients with aggressive NHL. Preliminary results of the GISL LA05 Trial. Blood 2006; 108: 689a (Abstr 2434).
15. Gobbi PG, Ghirardelli ML, Cavalli C et al. The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas. Haematologica 2000; 85: 372-80.
16. Merli F, Bertini M, Luminari S et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 367-373.
17. Merli F, Bertini M, Sacchi S et al. A pilot study with an oral chemotherapy regimen (CIEP) in the treatment of diffuse large cell lymphoma (DLCL) in elderly patients: an interim report from Italian Lymphoma Intergroup (ILI). Ann Oncol 2002; 13 (Suppl 2): 156 (Abstr 554).
18. Merli F, Vitolo U, Luminari S et al. R-CHOP vs R-mini-CEOP in elderly patients with diffuse large B cell lymphoma: an interim report from Intergruppo Italiano Linfomi (IIL). Blood 2005; 106: 262b (Abstr 4729).
19. Luminari S, Cesaretti M, Rashid I et al. Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. Hematol Oncol 2007; 25: 189-97.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Cox D. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
22. Van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival models. Stat Med 2000; 19: 3401-3415.
23. Harrell FE Jr, Lee KL, Mark DB. Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.